Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of QMF149 in Japanese Patients with Asthma
NCT03100500Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in asthma, sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
fexuprazan
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03100500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100500.